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Abstract.
Background: Parkinson’s disease (PD) patients with 20 years or more survival (PD-20) are not well characterized.
Objective: To evaluate PD-20 patient characteristics and identify areas for improvement of their health care.
Methods: The international, multicenter National Parkinson’s Foundation Quality Improvement Initiative (NPF-QII) study
database was queried to identify PD-20 subjects. Demographic and clinical data were analyzed.
Results: We identified 187 PD-20 subjects (55% men) representing 4% (187/4,619) of all NPF-QII participants. Subjects were
mean age 69.5 years; mean age at PD onset was 44.0 years. The majority (75%) had 20-25 years of PD duration, the longest
duration being 49 years. They were median Hoehn and Yahr stage 3, and 75% had motor fluctuations. Half (54%) reported
exercising. The majority (89%) were living at home and required a caregiver (88%). They were mildly cognitively impaired for
age (Montreal Cognitive Assessment estimate 22.6 ± 3.7), with most deficits in verbal fluency and delayed recall. Quality of life
(Parkinson’s Disease Quality of Life Questionnaire index 36 ± 15%) was mild to moderately impaired, with most impairment in
mobility and activities of daily living. Caregiver strain measured by the Multidimensional Caregiver Strain Index (27 ± 16%),
recorded highest subscores in social constraint. PD-20 subjects aged <70 years versus ≥70 only differed significantly by worse
cognition (P < 0.0001).
Conclusions: PD-20 subjects reflect an elite group of PD survivors with early-onset disease and relatively mild cognitive
disability despite long disease duration. Interventions for caregivers, mobility, and activities of daily living are areas that could
improve caregiver burden and patient quality of life.
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INTRODUCTION
Parkinson’s disease (PD) patients have shortened
survival when compared with age-matched controls
[1–4]. Several risk factors negatively impact PD
survival including demographic factors, such as older
age at onset [1]; PD factors, such as psychosis, demen-
tia, and motor severity [4, 5]; and non-PD factors,
such as pneumonia and cachexia [3]. Very few PD
patients survive beyond 20 years, particularly those
who develop PD in their seventh or eighth decades.
Natural history studies are limited but suggest demen-
tia and nursing home placement are almost inevitable
in those who reach the 20-year milestone [6]. Con-
sequently, PD patients with long-term survival of
20 years or greater have not been well character-
ized. Hence, the aim of this study was to describe
PD-20 patients derived from a large community-
dwelling cohort. Characterization of these patients
may reveal favorable factors for survival in PD. It
may also help improve health care delivery in this
population.
METHODS
Study design
The international, multicenter National Parkinson
Foundation’s Quality Improvement Initiative (NPF-
QII) study database prospectively records annual data
on PD subjects from 20 NPF Centers of Excellence
in the United States, Canada, Netherlands, and Israel
[7]. At the time of the study, NPF-QII was in its third
year of enrollment, having registered 4,619 PD partic-
ipants. All enrolled subjects provide written informed
consent.
The NPF-QII dataset was queried in a cross-
sectional manner to identify and characterize PD-20
subjects. Demographic and clinical data extracted
included gender, race, age at onset, age at diagnosis,
disease duration, presence of tremor, motor fluctua-
tions, Hoehn and Yahr stage, co-morbidities, living
situation, presence or absence of a regular care partner,
exercise, hospital and emergency room visits within the
past year, medications, and other treatments (physical
therapy, occupational therapy, speech therapy). Data
instruments included Timed Up and Go test [8], Parkin-
son’s Disease Quality of Life Questionnaire (PDQ-39)
[9], Multiple Caregiver Strain Index (MCSI) [10],
and Montreal Cognitive Assessment (MoCA) estimate
[11] scores. The PDQ-39 is a validated, health-related,
quality of life (QoL) scale that is completed by the
subject and measures health status and impact of PD
on daily life. There are 39 items subdivided into eight
domains: mobility, activities of daily living (ADLs),
emotional well-being, stigma, social support, cogni-
tion, communication, and bodily discomfort. The sum
score is expressed as a percentage (PDQ index, %),
where 0% is no disability and 100% is maximum dis-
ability [9]. MCSI is an 18-item tool completed by the
caregiver, measuring 6 domains of subjective response
to stressors. Subscores include physical strain, social
constraints, financial strain, time constraints, inter-
personal strain, and elder demanding/manipulative.
Similar to the PDQ-39, the MCSI is expressed as an
index percentage [10]. The scale has not been validated
in PD, but expert review recommended this was appro-
priate for the PD population [7]. The MoCA estimate,
a weighted cognitive score formed from a combination
of immediate and delayed 5-word recall and semantic
fluency (animals) scores to optimally predict MoCA
[11] results, was concurrently collected at one cen-
ter (University of Pennsylvania). Multiple medication
use was defined as 2 or more medications. A sub-
group analysis comparing PD-20 patients aged <70
years versus ≥70 years was also performed to assess
whether current age may be a factor in the recorded
outcomes. We arbitrarily chose age 70, where patients
younger than age 70 would have had PD onset before
age 50.
Statistical analysis
Standard descriptive statistics were used for mean
and standard deviation values. For comparison of
PD-20 subjects <70 versus ≥70 years old, Student
t and chi-square tests were conducted. The statistical
significance was set at P < 0.0001.
Fig. 1. Disease duration of PD-20 subjects (N = 187).
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Table 1
Comparison of demographic and clinical characteristics for PD-20 patients with those aged <70 years versus those ≥70 years
Overall PD-20 Age P Value
(N = 187) <70 yrs (N = 97) ≥70 (N = 90)
Demographic variables
Male, N (%) 103 (55%) 54 (56%) 49 (54%) 0.866
Age of onset, mean ± SD 44.0 ± 9.0 38.8 ± 6.5 49.8 ± 7.8 <0.0001∗
Current age, mean ± SD 69.5 ± 8.3 63.2 ± 5.0 76.3 ± 5.1 <0.0001*
Social variables
Living situation, N (%)
At home 166 (89%) 91 (94%) 75 (83%) 0.062
Skilled care 19 (10%) 5 (5%) 14 (16%)
Other 2 (1%) 1 (1%) 1 (1%)
Regular care partner, N(%)
No 22 (12%) 15 (16%) 7 (8%) 0.021
Spouse/partner 128 (68%) 68 (70%) 60 (67%)
Other relative 20 (11%) 8 (8%) 12 (13%)
Paid caregiver 14 (8%) 3 (3%) 11 (12%)
Other 3 (2%) 3 (3%)
Clinical variables
Certainty of idiopathic PD 174 (94%) 95 (98%) 79 (90%) 0.019
diagnosis ≥90%
Rest tremor present 101 (55%) 48 (50%) 53 (60%) 0.192
Motor fluctuations 140 (75%) 73 (75%) 67 (74%) 0.898
Standardized TUG (sec) 0.6 ± 1.0 0.4 ± 1.1 0.9 ± 0.9 0.001
Immediate word recall 3.9 ± 1.1 4.2 ± 0.9 3.6 ± 1.2 0.0004
Delayed word recall 2.5 ± 1.4 2.9 ± 1.3 2.0 ± 1.4 <0.0001∗
Verbal fluency 15.2 ± 6.2 16.4 ± 6.5 13.9 ± 5.7 0.006
MoCA estimate 22.6 ± 3.7 23.7 ± 3.3 21.3 ± 3.7 <0.0001∗
Comorbidities 1.9 ± 1.3 1.9 ± 1.4 2.0 ± 1.2 0.643
Deep brain stimulation, N (%) 84 (45%) 64 (66%) 20 (22%) <0.0001∗
Hospital/ER visit, N (%)
Missing 51 (27%) 25 (26%) 26 (29%) 0.310
None 80 (43%) 44 (45%) 36 (40%)
Hospital only 17 (9%) 12 (12%) 5 (6%)
ER only 16 (9%) 7 (7%) 9 (10%)
Hospital and ER 23 (12%) 9 (9%) 14 (16%)
Medications, N (%)
Any form of levodopa 182 (98%) 93 (97%) 89 (99%) 0.344
Dopamine agonist 74 (40%) 41 (43%) 33 (37%) 0.400
MAO-B inhibitor 32 (17%) 13 (14%) 19 (21%) 0.182
COMT inhibitor 56 (30%) 32 (33%) 24 (27%) 0.322
Amantadine 68 (37%) 42 (44%) 26 (29%) 0.031
Antidepressant medications 75 (40%) 48 (50%) 27 (30%) 0.006
Cognitive enhancers 29 (16%) 11 (12%) 18 (20%) 0.115
Stimulants 4 (2%) 3 (3%) 1 (1%) 0.344
Antipsychotic medications 25 (14%) 9 (9%) 16 (18%) 0.082
Anticholinergic medications 12 (7%) 9 (10%) 3 (3%) 0.090
Other treatments, N (%)
Physical therapy 87 (47%) 42 (43%) 45 (50%) 0.359
Occupational therapy 37 (20%) 11 (11%) 26 (29%) 0.003
Speech therapy 40 (21%) 22 (23%) 18 (20%) 0.655
Exercise 100 (54%) 47 (49%) 53 (59%) 0.153
Social worker/counseling 25 (13%) 12 (12%) 13 (15%) 0.655
No mental health therapy/referral 16 (9%) 12 (12%) 4 (4%) 0.053
PDQ-39, mean±SD
PDQ39 mobility 22.1 ± 11.7 19.9 ± 11.7 24.4 ± 11.4 0.008
PDQ39 ADL 12.1 ± 6.7 10.7 ± 6.4 13.7 ± 6.6 0.003
PDQ39 emotion 7.3 ± 5.3 7.3 ± 5.4 7.3 ± 5.2 0.978
PDQ39 stigma 3.8 ± 3.4 3.8 ± 3.4 3.7 ± 3.6 0.774
PDQ39 social support 2.2 ± 2.3 2.3 ± 2.4 2.0 ± 2.1 0.292
PDQ39 cognition 5.6 ± 3.4 5.3 ± 3.5 6.0 ± 3.3 0.151
PDQ39 communication 4.8 ± 3.0 4.9 ± 3.0 4.7 ± 3.0 0.583
PDQ39 pain 4.4 ± 2.9 4.5 ± 2.9 4.3 ± 3.0 0.745
PDQ39 summary index (%) 35.8 ± 16.3 34.3 ± 16.8 37.4 ± 15.7 0.204
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Table 1
(Continued)
Overall PD-20 Age P Value
(N = 187) <70 yrs (N = 97) ≥70 (N = 90)
MCSI, mean±SD
Physical strain 3.5 ± 2.9 3.5 ± 2.9 3.5 ± 2.9 0.937
Social constraints 6.3 ± 3.7 6.0 ± 4.1 6.7 ± 3.4 0.334
Financial strain 1.2 ± 1.4 1.1 ± 1.3 1.3 ± 1.5 0.575
Time constraints 3.4 ± 2.2 3.4 ± 2.2 3.5 ± 2.1 0.844
Interpersonal strain 3.4 ± 3.0 3.2 ± 3.1 3.5 ± 2.9 0.679
Elder demanding/manipulative 1.2 ± 1.6 0.9 ± 1.4 1.6 ± 1.8 0.023
MCSI index (%) 26.5 ± 16.0 25.1 ± 16.2 27.8 ± 15.8 0.349
ADL, activities of daily living; COMT, catechol-O-methyl transferase; ER, emergency room; MAO, monoamine oxidase; MCSI, Multiple Care-
giver Strain Index; MoCA, Montreal Cognitive Assessment; PD, Parkinson’s disease; PDQ, Parkinson’s Disease Quality of Life Questionnaire;
TUG, timed up and go. ∗P < 0.0001 significant.
RESULTS
There were 187 PD-20 subjects (55% men), rep-
resenting 4% (187/4,619) of all PD subjects in the
NPF-QII study (Table 1). PD-20 subjects were mean
age 69.5 years old (±8.3 years), with a mean age
of onset of 44.0 years (±9.0 years). All had PD
onset before age 66. The majority (75%) had 20–25
years of PD duration, and the longest duration was
49 years (Fig. 1). They were median Hoehn and Yahr
stage 3, with rest tremor reported by 55%, and motor
fluctuations in 75%. Almost all (98%) were taking
levodopa, with dopamine agonists (40%) and amanta-
dine (37%) the next most commonly used medications
for motor symptoms. Antidepressants (40%), cogni-
tive enhancers (16%), and antipsychotics (14%) were
the most commonly used medications for non-motor
symptoms. Eighty-four (45%) had undergone deep
brain stimulation (DBS). Just over half (54%) reported
some form of exercise, although the frequency and
intensity was not known. The use of therapists occurred
in a minority of patients. A large proportion (41%)
had either visited the emergency room or had been
admitted to hospital in the last year. Encouragingly, the
vast majority (89%) were still living at home, although
most required a caregiver (88%). They were on average
mildly cognitively impaired for age (MoCA estimate
22.6 ± 3.7), with most impairment in verbal fluency
and delayed recall. Patient self-reported QoL was mild
to moderately impaired (PDQ-39 index 36 ± 15%),
with highest subscores in mobility and ADLs. Care-
giver strain was also mild to moderately impaired
(27 ± 16%), with highest subscores in social constraint.
Comparison of PD-20 patients aged < 70 years old
versus ≥70, revealed that they differed significantly by
worse cognition (measured by delayed word recall and
MOCA estimate) (P < 0.0001). Those younger than 70
were more likely to have undergone DBS (64 [66%]
versus 20 [22%]; P < 0.0001). They were otherwise
similar in all other domains, including medication use,
mobility scores, likelihood of requiring a relative or
paid caregiver, caregiver strain, and perceived QoL
(Table 1).
DISCUSSION
PD subjects enrolled in the NPF-QII study that sur-
vived 20 years or longer had a more robust health status
than anticipated.; they were not inevitably demented
or residing in nursing homes [6]. The most apparent
explanation is the PD-20 population had earlier onset
disease, on average in the fifth decade compared with
the seventh decade for PD cases overall. Early-onset
PD is known to predict a milder disease course with
longer survival and less disability compared to later-
onset PD [5, 12, 13]. In addition, early-onset PD is
more likely to include patients with autosomal reces-
sive genetic variants [14]. These hereditary forms are
commonly pure motor phenotypes with long disease
duration [15]. It is likely that a proportion of our PD-20
patients had genetic variants, although this information
was not captured in the NPF-QII study. The proportion
of male subjects was lower (55% vs 45% female; ratio
1.2:1.0) than the reported overall PD ratio of 1.5-2.5
times higher in males [16]. Higher male mortality has
been reported in the normal elderly as well as other
chronic diseases. Female gender may be a protective
factor for longer disease duration, possibly relating
to hormonal or other gender-specific factors [16–18].
There were less tremor-predominant PD patients than
anticipated, as the presence of tremor is reported to
confer a more benign course with slower disease pro-
gression [19–21]. Tremor in our cohort may have
been masked by PD drugs, or an artifact of the study
recording protocol (examiner classification vs. strict
classification).
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Surprisingly, a high proportion of PD-20 subjects
were still living at home (89%). This percentage was
lower than that reported in a study of NPF-QII patients
with 10 years PD survival [22], probably reflective
of disease progression. The need for caregivers in
this population (88%) is important to highlight and
has implications for increased costs of care. Another
important finding was caregiver burden, which also
translates to higher costs [23, 24]. Likewise, almost
half of the PD-20 subjects visited an emergency room
or a hospital in the past year, which would also increase
cost of care [23]. Of interest is that half of the patients
reported exercising, although the type, frequency, and
intensity were not recorded. This warrants further
study, particularly given the postulated neuroprotective
effect of exercise in dementia and Parkinson’s disease.
Almost half had undergone DBS; whether this could be
a factor relating to better survival is unknown, and will
need to be examined in future prospective case-control
natural history studies.
Remarkably, there was little difference between
PD-20 subjects aged <70 years old versus those ≥70.
The older subjects had worse function in a single cogni-
tive domain (delayed verbal recall) likely explained by
the age difference [12, 13]. It is noteworthy that this did
not lead to a measurable difference in QoL, caregiver
burden, or increased use of cognitive enhancement
or antipsychotic medications. We anticipated worse
mobility in the older PD-20 group, but their motor per-
formance is likely an integral link to their survival.
Also, the absence of a difference in mobility could
explain why the QoL and caregiver burden was sim-
ilar for the two subgroups, as impaired gait impacts
QoL [25]. Those younger than age 70 had significantly
higher rates of DBS treatment, which is not surprising
given the risks of DBS surgery increase in those above
age 70. However, the age at which DBS was performed
was not recorded.
There has been a paucity of data on long-term
PD survivors to date [5, 6]. The Sydney Multicenter
Study followed 136 community-dwelling PD patients
over a 20-year period. Of the 36 survivors, 83% were
demented and almost all were nursing home residents
according to Hely et al. [6]. This has helped to shape
a pessimistic view amongst neurologists that patients
surviving 20 years and beyond are destined to have a
poor prognosis. However, our findings highlight that
this is not universal. While ours is a cross-sectional
study, and therefore cannot be directly compared with
the Hely study, it does demonstrate that certain PD
patients may survive for two decades or more and
have a reasonably acceptable QoL, still residing at
home with retained cognition. The important lesson
for neurologists is that these patients are likely to be
encountered in PD clinics after 20 years of PD duration
and functioning reasonably well.
The major limitation of our study is its cross-
sectional nature. There is survival bias, as the original
denominator of the PD-20 patients is unknown. There
is sampling bias for PD patients attending NPF centers
and enrollment bias for PD subjects listed in the NPF-
QII study. Thus, PD-20 subjects with severe dementia
or residing in a nursing home may not be represented
in the NPF-QII. The study strengths are utilization of a
uniform dataset and identification of the PD-20 subset
from multiple geographic real-world clinics.
Despite the positive picture that emerged in our
PD-20 subjects, the mild to moderate impairment in
QoL, and the mild to moderate caregiver burden will be
important to address. Early prevention of motor symp-
tom progression, dementia, and psychosis has been
suggested as an important direction for increasing life
expectancy in PD [5], although there are no existing
preventive medications or strategies. The prospective
nature of the NPF-QII clinical study enhances its abil-
ity to provide this type of information.
In conclusion, subjects surviving 20 years or longer
with PD largely represent an elite subset of patients
with early-onset disease, which is associated with a
more benign course. They have relatively mild cogni-
tive disability and continue to reside at home, despite
long disease duration. Support for PD-20 caregivers
could relieve caregiver burden, and targeting patient
mobility and ADLs could improve PD-20 QoL. Fur-
ther prospective research will be necessary to identify
modifiable factors that confer long-term PD survival.
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